With DCGI Nod in hand, Roche launches Breast Cancer Drug Atezolizumab in India Medical Dialogues Bureau9 April 2020 7:00 AM GMTNew Delhi: Drug firm Roche India on Wednesday said it has launched immunotherapy drug Atezolizumab for the treatment of metastatic triple-negative...
Beximco Pharma announces Commercial Agreement with Mylan in Bangladesh Medical Dialogues Bureau25 Feb 2020 10:58 AM GMTBeximco Pharmaceuticals Limited, manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has announced the signing of a...
Merck Keytruda, Chemotherapy combo meets endpoint for first-line treatment of Breast Cancer Medical Dialogues Bureau18 Feb 2020 4:45 AM GMTNew Delhi: Merck known as MSD outside the United States and Canada, recently announced that the pivotal Phase 3 KEYNOTE-355 trial investigating...
Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list Medical Dialogues Bureau29 Nov 2019 3:45 AM GMTSeventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab,...
OncoStem Diagnostics named 'Best Innovation- Cancer Risk Assessment' by NASSCOM Life sciences and healthcare innovation forum Medical Dialogues Bureau29 Sep 2019 4:27 AM GMTBangalore, : OncoStem Diagnostics, an Oncology focused company that enables personalised cancer treatment was named as 'Best Innovation- Cancer Risk...
Mylan launches generic version of Faslodex Injection to treat breast cancer Medical Dialogues Bureau19 Sep 2019 4:05 AM GMTNew Delhi: Mylan N.V. recently announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic...
Allergan announces worldwide recall of textured breast implant tied to rare cancer Medical Dialogues Bureau26 July 2019 3:45 AM GMTThe U.S. Food and Drug Administration said it called for the removal after new information showed Allergan Inc's Biocell breast implants account for a...
Novartis wins USFDA approval for first PI3K inhibitor for breast cancer Farhat Nasim27 May 2019 12:40 PM GMTThe drug, alpelisib, to be marketed under the brand name Piqray, belongs to a class of drugs known as PI3K inhibitors and is the first of its kind to...
AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise Medical Dialogues Bureau10 May 2019 3:30 AM GMTThe treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
AstraZeneca ties up with Transgene to develop viral immunotherapies Garima2 May 2019 3:55 AM GMTAstraZeneca has been moving deeper into cancer therapy market through wide-ranging deals, including those for immunotherapy and targeted therapy.New...
Pfizer gets CHMP opinion for Talzenna for patients with metastatic breast cancer Farhat Nasim29 April 2019 4:05 AM GMTThe positive CHMP opinion of TALZENNA follows the medicine's approval by the U.S. Food and Drug Administration (FDA) in October 2018.New Delhi:...
Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate Meghna A Singhania11 April 2019 5:20 AM GMTMumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...